About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 54 record(s)
Req # A-2024-54596
Submission of the Public Health Agency of Canada (PHAC) to the Patented Medicine Prices Review Board’s November 2023 consultation on the Scoping paper of the Board's Guidelines. Submissions from other stakeholders can be viewed here: https://www.canada.ca/en/patented-medicine-prices-review/services/consultations/scoping-paper-board-guidelines.htmlOrganization: Patented Medicine Prices Review Board Canada
February 2024
Nothing to report this month
Organization: Nunavut Impact Review Board
Req # A-2021-024942
Provide all emails sent to/from/cc'ing Douglas Clarke between May 1 to December 16, 2021. Exclude media scans.Organization: Patented Medicine Prices Review Board Canada
September 2023
Req # A-2023-36126
When referring to page numbers below, I mean the pages in the Client Package disclosed under A-2022-05111. Specifically, I would like to request the following: 1. The "Board deck" (presumably a PowerPoint presentation) mentioned on pages 21-27. 2. The powerpoint attached to the email on page 47, which apparently deals with discrepancies between dTCC data. 3. The media lines attached to the email on page 95. 4. The excel sheet attached to the email on page 98. 5. The presentation attached to the email on page 135. 6. Both attachments to the email on page 135, plus the two documents that are linked to in the email: the impact estimates and communication plan. 7. The attachment to the email on page 142. 8. The "Key messages" document linked to in the body of the email on page 145. 9. The Excel file attached to the email on page 165. 10. I would like any contextual documents related to the document which appears on pages 359-360 ("Brochure: 2020 Rent Increase Guidelines). I imagine this was an attachment to an email, in which case I would like the email (possibly pages 4368-4369 of the raw request). I would also like to request any other documents related to how the brochure was located by the PMPRB, or what use was made of the Brochure by the PMPRB (like subsequent email discussions or meeting agendas which list this document, or reports or memos written about this document, etc). In each case, I would like the most recent or final version. I do not need drafts. Please exclude cabinet confidences.Organization: Patented Medicine Prices Review Board Canada
September 2023
Nothing to report this month
Organization: Nunavut Impact Review Board
Req # A-2023-02395
Copies of all correspondence and communications between the (then) acting chairperson of the Patented Medicines Prices Review Board Mélanie Bourassa-Forcier and Innovative Medicines Canada (IMC) between October 1, 2022 and December 5, 2022 regarding the PMPRB's new draft guidelines and the consultation process. Please include all responses to Innovative Medicines Canada (IMC)'s communications/correspondence from the (then) acting chairperson of the Patented Medicines Prices Review Board Mélanie Bourassa-Forcier.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09063
Copies of any emails sent by the Vice-chair regarding any of the following topics: (i) her resignation or intent to resign or the reasons for her resignation. (ii) the draft guidelines. (iii) the consultation process for the draft guidelines. (iv) the impact of the Merck Canada, IMC, and/or Alexion court decisions on the PMPRB, including its draft guidelines. From November 1, 2022 to December 5, 2022.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09228
All correspondence between PMPRB Board members and PMPRB staff pertaining to the October 2022 revised draft Guidelines and the resignation of the PMPRB Acting Chairperson, Mélanie Bourassa-Forcier. “Correspondence” includes written correspondence, call notes, email, text messaging, instant messaging, and any other form of electronic communication.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09229
All correspondence between the former PMPRB Acting Chairperson, Melanie Bourassa-Forcier, and the Minister of Health Jean-Yves Duclos (including the Minister’s staff), or Deputy Minister of Health Stephen Lucas (including the Deputy Minister’s staff), about the PMPRB October 2022 revised draft Guidelines and the resignation of PMPRB Acting Chairperson, Melanie Bourassa-Forcier. “Correspondence” includes written correspondence, call notes, email, text messaging, instant messaging, and any other form of electronic communication.Organization: Patented Medicine Prices Review Board Canada
February 2023
Req # A-2022-09230
All correspondence between PMPRB Executive Director Doug Clark and the Minister of Health Jean-Yves Duclos (including the Minister’s staff), or Deputy Minister of Health Stephen Lucas (including the Deputy Minister’s staff), about the PMPRB October 2022 revised draft Guidelines and the resignation of PMPRB Acting Chairperson, Melanie Bourassa-Forcier. “Correspondence” includes written correspondence, call notes, email, text messaging, instant messaging, and any other form of electronic communication.Organization: Patented Medicine Prices Review Board Canada
February 2023